Bone age is the best predictor of growth response to recombinant human growth hormone in Turner’s syndrome.
Indian J Hum Genet
;
2010 Sept; 16(3): 119-126
Artículo
en Inglés
| IMSEAR
| ID: sea-138910
ABSTRACT
BACKGROUND AND OBJECTIVES:
Recombinant human growth hormone (rhGH) is approved for use in children with Turner’s syndrome (TS) in most industrialized countries and is recommended in the recently issued guidelines. We determined the growth responses of girls who are treated with rhGH for TS, with an aim to identify the predictors of growth response. MATERIALS ANDMETHODS:
Fifty-six prepubertal girls with TS, documented by peripheral blood karyotype, were enrolled. All the patients received biosynthetic growth hormone therapy with a standard dose of 30 IU/m2/week. The calculated dose per week was divided for 6 days and given subcutaneously at night.RESULTS:
This study showed that rhGH therapy provides satisfactory auxological results. Bone age delay is to be considered as a predictive factor which may negatively influence the effect of rhGH therapy on final height. The growth velocity in the preceding year is the most important predictor of rhGH therapy response.CONCLUSION:
These observations help us to guide rhGH prescription, to reduce the risks and costs.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Síndrome de Turner
/
Femenino
/
Humanos
/
Determinación de la Edad por el Esqueleto
/
Niño
/
Pubertad
/
Hormona de Crecimiento Humana
/
Egipto
Tipo de estudio:
Guía de Práctica Clínica
/
Estudio pronóstico
País/Región como asunto:
Africa
Idioma:
Inglés
Revista:
Indian J Hum Genet
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS